Additional file 1 of Percutaneous dilatational tracheotomy in high-risk ICU patients

Additional file 1: Table S1. Complications during and after PDT differentiated by body mass index (BMI). p-values < 0.05 were considered as significant; ns: non-significant. Of note, there were 9 patients with BMI value < 16 kg/m2 and 12 patients with BMI value > 40 kg/m2 who were not included. Table S2. Baseline characteristics (based on seven treatment groups): I) Intravenous unfractionated heparin (iUFH) (prophylactic dosage), II) iUFH (therapeutic dosage), III) aspirin (100 mg/day) and iUFH (prophylactic dosage) IV) aspirin (100 mg/day) and iUFH (therapeutic dosage), V) P2Y12 receptor inhibitor, i.e. clopidogrel (75 mg/day), prasugrel (10 mg/day) or ticagrelor (90 mg twice daily) with iUFH (therapeutic dosage), VI) DAPT including aspirin (100 mg/day) and a P2Y12 receptor inhibitor with iUFH (prophylactic dosage) and VII) DAPT with iUFH (therapeutic dosage), i.e. triple therapy. All displayed laboratory values were recorded on the day of PDT 4 h prior to procedure. ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; INR, International Normalized Ratio; aPTT, activated Partial Thromboplastin Time; SD, standard deviation. Table S3. Procedural related complications during and after PDT (based on seven treatment groups). p-values < 0.05 were considered as significant; ns: non-significant.